echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Ascent Pharma’s Bcl-2 selective inhibitor APG-2575 for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma for the key registration phase II clinical study was approved by CDE

    Ascent Pharma’s Bcl-2 selective inhibitor APG-2575 for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma for the key registration phase II clinical study was approved by CDE

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Suzhou, China and Rockville, Maryland, U.


    APG2575CC201 is a single-arm, open key registration phase II clinical study in R/R CLL/SLL patients to evaluate the effectiveness and safety of APG-2575


    APG-2575 is a new type of oral Bcl-2 selective small molecule inhibitor under research by Ascent Pharmaceuticals, which can restore the programmed death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis , To achieve the purpose of treating tumors


    There is still a huge unmet need for treatment in the global CLL/SLL treatment field


    Dr.


    About Lisaftoclax (APG-2575)

    APG-2575 is a new type of oral Bcl-2 selective small molecule inhibitor under research by Ascent Pharmaceuticals, which can restore the programmed death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis , To achieve the purpose of treating tumors


    APG-2575 has been carried out in the United States, China, Australia, Europe and other places around the world, including the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, breast cancer, and other blood tumors and solid tumors clinical research


    About Yasheng Pharmaceutical

    Yasheng Pharmaceutical is a biomedical company based in China and facing the world.


    Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world


    Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights globally, and cooperated with leading biotechnology companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, and Pfizer.


    Forward-looking statement

    The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article


    Source: Yasheng Pharmaceutical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.